Current Treatment Approaches for Transformed Indolent B-Cell Lymphomas
Education about the recent advances and special considerations associated with the diagnosis and management of transformed indolent lymphomas is essential to facilitate the incorporation of novel treatment options into routine clinical practice to improve clinical outcomes.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • 0.75 ANCC contact hours
  • 0.75 Participation
Cost $0.00
Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma
Follicular lymphoma (FL) is characterized by multiple recurrences requiring retreatment. In recent years, EZH2 inhibitors and chimeric antigen receptor (CAR) T-cell therapies have been approved for relapsed/refractory FL after ≥2 prior systemic therapy regimens.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Cost $0.00
Management of TP53 Mutated Mantle Cell Lymphoma
Classical mantle cell lymphoma (MCL) with TP53 mutation is associated with inferior survival outcomes to induction chemoimmunotherapy and autologous hematopoietic cell transplant, especially in younger patients.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Cost $0.00
CAR T-Cell Therapies in Hematologic Malignancies: Challenges and Strategies
Multiple CAR T-cell therapies are approved for the treatment of certain relapsed or refractory hematologic malignancies with promising clinical outcomes. However, treatment with CAR T-cell therapy is not without risk and can result in severe and potentially fatal toxicities.
Category
  • Acute Lymphoblastic Leukemia
  • Hematologic Malignancies
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Cost $0.00
Optimizing the Use of Bispecific Antibodies in Hematologic Malignancies
Immunotherapy using antibody drug conjugates, immune check point inhibitors, and chimeric antigen receptor (CAR) T-cells has significantly transformed the treatment landscape of relapsed or refractory hematologic malignancies.
Category
  • Acute Lymphoblastic Leukemia
  • Hematologic Malignancies
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Cost $0.00
Debate: Is the Addition of Polatuzumab Vedotin the New Standard First-Line Therapy for Diffuse Large B-Cell Lymphoma?
Polatuzumab vedotin in combination with R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) has emerged as a new first-line therapy option for patients with advanced stage diffuse large B-cell lymphomas (DLBCL).
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Cost $0.00
Diffuse Large B-Cell Lymphoma: Sequencing Therapy for Relapsed/Refractory Disease
The advent of novel targeted therapies represents a major paradigm shift for management of relapsed or refractory diffuse large B-cell lymphomas (DLBCL).
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Cost $0.00